Császár A - Search Results

1

Elevation of monocyte-platelet aggregates is an early marker of type 2 diabetes.

Patkó Z, Császár A, Acsády G, Ory I, Takács E, Fűrész J. Patkó Z, et al. Among authors: csaszar a. Interv Med Appl Sci. 2012 Dec;4(4):181-5. doi: 10.1556/IMAS.4.2012.4.2. Epub 2012 Dec 27. Interv Med Appl Sci. 2012. PMID: 24265874 Free PMC article.

2

Roles of Mac-1 and glycoprotein IIb/IIIa integrins in leukocyte-platelet aggregate formation: stabilization by Mac-1 and inhibition by GpIIb/IIIa blockers.

Patko Z, Csaszar A, Acsady G, Peter K, Schwarz M. Patko Z, et al. Among authors: csaszar a. Platelets. 2012;23(5):368-75. doi: 10.3109/09537104.2011.625098. Epub 2012 Jun 6. Platelets. 2012. PMID: 22671289 Free article.

3

Association of plasma lipid levels with apolipoprotein E polymorphism in Type 2 diabetes.

Kalina A, Szalai C, Prohászka Z, Reiber I, Császár A. Kalina A, et al. Among authors: csaszar a. Diabetes Res Clin Pract. 2002 Apr;56(1):63-8. doi: 10.1016/s0168-8227(01)00350-3. Diabetes Res Clin Pract. 2002. PMID: 11879722

4

Chemokine receptor CCR2 and CCR5 polymorphisms in children with insulin-dependent diabetes mellitus.

Szalai C, Császár A, Czinner A, Szabó T, Pánczél P, Madácsy L, Falus A. Szalai C, et al. Among authors: csaszar a. Pediatr Res. 1999 Jul;46(1):82-4. doi: 10.1203/00006450-199907000-00014. Pediatr Res. 1999. PMID: 10400139

5

Hypertriglyceridemia, the coronary heart disease risk marker "solved".

Császár A. Császár A. Acta Physiol Hung. 2005;92(2):109-20. doi: 10.1556/APhysiol.92.2005.2.2. Acta Physiol Hung. 2005. PMID: 16268049 Review.

6

Cytokine regulation of the acute-phase protein levels in multiple myeloma.

Bíró L, Domján G, Falus A, Jakab L, Cseh K, Kalabay L, Tarkovács G, Tresch J, Malle E, Kramer J, Prohászka Z, Jákó J, Füst G, Császár A. Bíró L, et al. Among authors: csaszar a. Eur J Clin Invest. 1998 Aug;28(8):679-86. doi: 10.1046/j.1365-2362.1998.00333.x. Eur J Clin Invest. 1998. PMID: 9767364

7

Correlation between flow-mediated dilation and erectile dysfunction.

Kovács I, Császár A, Toth J, Siller G, Farkas A, Tarján J, Horváth J, Koller A. Kovács I, et al. Among authors: csaszar a. J Cardiovasc Pharmacol. 2008 Feb;51(2):148-53. doi: 10.1097/FJC.0b013e31815e8514. J Cardiovasc Pharmacol. 2008. PMID: 18287882

8

Polymorphism in the promoter region of the apolipoprotein A5 gene is associated with an increased susceptibility for coronary artery disease.

Szalai C, Keszei M, Duba J, Prohászka Z, Kozma GT, Császár A, Balogh S, Almássy Z, Fust G, Czinner A. Szalai C, et al. Among authors: csaszar a. Atherosclerosis. 2004 Mar;173(1):109-14. doi: 10.1016/j.atherosclerosis.2003.12.003. Atherosclerosis. 2004. PMID: 15177130

9

The characteristics of two LDL-cholesterol level reduction treatment strategies, "treat-to-target" and "percent reduction": an observational study without intervention.

Császár A. Császár A. BMC Cardiovasc Disord. 2019 Mar 11;19(1):57. doi: 10.1186/s12872-019-1038-y. BMC Cardiovasc Disord. 2019. PMID: 30857520 Free PMC article.

10

Frequency of the R3500Q mutation of the apolipoprotein B-100 gene in a sample screened clinically for familial hypercholesterolemia in Hungary.

Kalina A, Császár A, Czeizel AE, Romics L, Szabóki F, Szalai C, Reiber I, Németh A, Stephenson S, Williams RR. Kalina A, et al. Among authors: csaszar a. Atherosclerosis. 2001 Jan;154(1):247-51. doi: 10.1016/s0021-9150(00)00648-1. Atherosclerosis. 2001. PMID: 11137107

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

213 results

Search Page

Filters